Wednesday, April 29, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The Future of LLMs in Healthcare

In this episode, the host discusses the significance of large language models (LLMs) in healthcare, their applications, and the challenges they face. The conversation highlights the importance of simplicity in model design and the necessity of integrating patient feedback to enhance the effectiveness of LLMs in clinical settings.
Takeaways

  • LLMs are becoming integral in healthcare.
  • They can help determine costs and service options.
  • Hallucination in LLMs can lead to misinformation.
  • LLMs can produce inconsistent answers based on input.
  • Simplicity in LLMs is often more effective than complexity.
  • Patient behavior should guide LLM development.
  • Integrating patient feedback is crucial for accuracy.
  • Pre-training models with patient input enhances relevance.
  • Healthcare providers must understand LLM limitations.
  • The best LLMs will focus on patient-centered care.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!